Lynne Abruzzo

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia
    Carmen D Schweighofer
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e28277. 2011
  2. pmc Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression
    Joan H Admirand
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Mod Pathol 23:1518-23. 2010
  3. pmc Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology
    Lynne V Abruzzo
    University of Texas M D Anderson Cancer Center, Department of Hematopathology, Box 72, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Mol Diagn 9:546-55. 2007
  4. ncbi Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms
    Lynne V Abruzzo
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg Pathol 26:630-6. 2002
  5. ncbi Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
    Yiming Chen
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:2507-13. 2011
  6. doi The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia
    Ravin Garg
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3531-7. 2012
  7. ncbi Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis
    Anuradha Kanungo
    Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 19:25-33. 2006
  8. doi Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients
    Constantine S Tam
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 141:36-40. 2008
  9. ncbi p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
    Ellen J Schlette
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 50:1597-605. 2009
  10. ncbi Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
    William G Wierda
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:4088-95. 2011

Detail Information

Publications58

  1. pmc A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia
    Carmen D Schweighofer
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e28277. 2011
    ..We optimized a two-gene model and validated it on an independent test set of 66 samples. This two-gene model predicted prognosis better on the test set than any of the known predictors, including ZAP70 and serum β2-microglobulin...
  2. pmc Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression
    Joan H Admirand
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Mod Pathol 23:1518-23. 2010
    ..03). These results show that ZAP70 expression assessed by immunohistochemistry is a reliable surrogate marker of the somatic mutation status of the IGHV genes, and predicts time to progression...
  3. pmc Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology
    Lynne V Abruzzo
    University of Texas M D Anderson Cancer Center, Department of Hematopathology, Box 72, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Mol Diagn 9:546-55. 2007
    ..Thus, we can classify cases with 95% accuracy based on the expression of as few as three genes...
  4. ncbi Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms
    Lynne V Abruzzo
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg Pathol 26:630-6. 2002
    ..Most are clonally distinct from the underlying low-grade B-cell neoplasm. A subset of these lesions may regress without systemic therapy...
  5. ncbi Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
    Yiming Chen
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:2507-13. 2011
    ....
  6. doi The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia
    Ravin Garg
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3531-7. 2012
    ..Although 13q deletion as the sole abnormality has been found to confer a favorable prognosis, there are little data as to whether there is a difference in prognostic value between monoallelic versus biallelic deletion of 13q...
  7. ncbi Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis
    Anuradha Kanungo
    Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 19:25-33. 2006
    ..However, this combination of molecular abnormalities can also rarely occur in other neoplasms, such as the cases of low-grade B-cell lymphoma and plasmablastic myeloma in this study...
  8. doi Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients
    Constantine S Tam
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 141:36-40. 2008
    ..Leukemic CD20 expression differed significantly between FISH subtypes. Patients with trisomy 12 CLL showed strong leukemic cell CD20 expression and had a high rate of response to rituximab-based therapy...
  9. ncbi p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
    Ellen J Schlette
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 50:1597-605. 2009
    ..In this patient cohort, p53-IHC is an important determinant of complete remission and overall survival, but not remission duration, in patients with CLL receiving FCR...
  10. ncbi Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
    William G Wierda
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:4088-95. 2011
    ..We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL...
  11. ncbi EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient
    C Cameron Yin
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 123:222-8. 2005
    ..To our knowledge, only 4 cases of both B-cell and T-cell PTLDs have been reported. Only 2 cases have been proven to be monoclonal and EBV-associated, as in this case, the first following kidney transplantation...
  12. ncbi De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
    Constantine S Tam
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Blood 114:957-64. 2009
    ..Patients with 17p- CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics...
  13. doi Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes
    C Cameron Yin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 131:663-70. 2009
    ..We conclude that CLL/SLL with t(2;14) (p16;q32) and BCL11A/IgH rearrangement is characterized by atypical morphologic features and unmutated IgV(H) genes...
  14. doi Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature
    Pei Lin
    Department of Hematopathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 39:1664-72. 2008
    ..These cases illustrate that t(18;22)(q21;q11) is more commonly observed in chronic lymphocytic leukemia and may represent either an initial or secondary genetic event...
  15. doi Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24)
    Pei Lin
    Department of Hematopathology, Box 72, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 193:119-22. 2009
    ..These findings extend the known disease spectrum associated with this cytogenetic aberration...
  16. ncbi del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia
    C Cameron Yin
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 192:18-23. 2009
    ..Del(15q) appears to be associated with a poor prognosis in CML...
  17. ncbi The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases
    Yang O Huh
    Department of Hematopathology, MD Anderson Cancer Centre, The University of Texas, Houston, TX 77030, USA
    Br J Haematol 136:220-8. 2007
    ..However, these neoplasms also differ from CLL cytologically and in their immunophenotype...
  18. doi Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:373-80. 2009
    ..An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic leukemia (CLL)...
  19. ncbi Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24)
    Patrick A Lennon
    School of Health Sciences, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Cancer Genet Cytogenet 177:37-42. 2007
    ..Western blot analysis detected EVI1 in one case analyzed. We conclude that the t(3;8)(q26;q24) results in deregulated EVI1 expression, similar to other balanced or unbalanced chromosomal translocations involving chromosome 3q26...
  20. ncbi A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
    Anas Younes
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:310-4. 2003
    ..Rituximab is used to primarily deplete normal B cells from HD lesions...
  21. doi MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis
    Yang O Huh
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 142:36-44. 2008
    ..In summary, MYC rearrangement, which occurs rarely in CLL patients, is associated with increased prolymphocytes, complex cytogenetic abnormalities, and a poor prognosis...
  22. ncbi Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia
    Pei Lin
    Department of Hematopathology, M D Anderson Cancer Center, Box 72, The University of Texas, Houston, TX 77030, USA
    Cancer Genet Cytogenet 166:82-5. 2006
    ..We conclude that the t(3;8)(q26;q24) is a recurrent translocation associated with therapy-related MDS/AML or de novo AML, and is frequently associated with monosomy 7...
  23. ncbi Cytogenetic findings in blastoid mantle cell lymphoma
    Joseph D Khoury
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Hum Pathol 34:1022-9. 2003
    ..03). We conclude that blastoid MCL tumors often show complex cytogenetic aberrations. Some abnormalities correlate with morphologic features, suggesting that morphologic variants of blastoid MCL may arise via different molecular pathways...
  24. ncbi Mantle cell lymphoma involving skin: cutaneous lesions may be the first manifestation of disease and tumors often have blastoid cytologic features
    Filiz Sen
    Division of Pathology and Loboratory Medicine, University of Texas M D Anderson Center, Houston, Texas 77030, USA
    Am J Surg Pathol 26:1312-8. 2002
    ..We conclude that mantle cell lymphoma can involve skin, usually as a manifestation of disseminated disease, and is often associated with blastoid cytologic features. Rare cases of mantle cell lymphoma may arise in skin...
  25. doi Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature
    Gary Lu
    Department of Hematopathology, Box 350, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Genet Cytogenet 188:118-23. 2009
    ..These cases often show features of myelomonocytic or monocytic differentiation. The prognosis is poor, with survival similar to other AML cases with unfavorable cytogenetic changes...
  26. doi Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features
    Sa A Wang
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leuk Res 35:351-7. 2011
    ..These clinicopathological features are likely attributed to commonly deleted regions of 11q and their involved genes...
  27. ncbi Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma
    Wei Lien Wang
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 21:1303-10. 2008
    ..Fluorescence in situ hybridization is useful to support the diagnosis of extraskeletal myxoid chondrosarcomas and may help to differentiate it from mimics such as other myxoid sarcomas, particularly in limited biopsies...
  28. doi microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
    Simona Rossi
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 116:945-52. 2010
    ..We conclude that the 21FK score represents a useful tool for distinguishing between good-prognosis and poor-prognosis CLL patients...
  29. doi Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome
    Sameer S Talwalkar
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Pathol Lab Med 134:1010-5. 2010
    ..Mutation carriers are at increased risk of multiple primary tumors, many of which arise in previous radiation-therapy sites. In patients with LFS, acute myeloid leukemia is uncommon and myelodysplastic syndrome (MDS) is rare...
  30. ncbi Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma
    Joan H Admirand
    Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 17:954-61. 2004
    ..In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods...
  31. pmc The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 115:5202-9. 2009
    ..To define the prognosis in myelodysplastic syndrome (MDS) and deletion 5q with or without other cytogenetic abnormalities...
  32. doi The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
    Constantine S Tam
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:4171-8. 2009
    ..Dynamic prognostic significance of cytogenetic abnormalities in PMF should be further prospectively evaluated...
  33. ncbi Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    Department of Leukemia and, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2991-5. 2007
    ..CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone...
  34. ncbi Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas
    Alexander Lazar
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    Arch Pathol Lab Med 130:1199-207. 2006
    ....
  35. ncbi Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
    Craig Kovitz
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 108:2811-3. 2006
    ..These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib...
  36. ncbi Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis
    Xin Han
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 125:49-56. 2006
    ..Of 3 patients treated with imatinib, 2 responded, but only 1 had a sustained response. CMPD with t(5;12) commonly transforms to blast phase, and transformation is associated with cytogenetic evidence of clonal evolution...
  37. pmc Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays
    Lynne V Abruzzo
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Mol Diagn 7:337-45. 2005
    ..A comprehensive list of all differentially expressed genes can only be obtained by combining the results of multiple statistical tests...
  38. doi Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
    Katherine I Lin
    Leukemia Department, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:3168-71. 2009
    ..8, P < .001). Our results suggest that postremission interventions should be targeted toward patients with unmutated IgV(H) status...
  39. ncbi Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  40. ncbi Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature
    Li Huang
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    Am J Clin Pathol 125:267-72. 2006
    ..A combination of conventional cytogenetic, and molecular analyses allows identification of these variants...
  41. ncbi Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease
    Xiaoping Sun
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 34:835-40. 2003
    ..These findings identify a differentially expressed growth regulatory receptor common to both FDC sarcoma and CD, identifying a target for possible therapy in unresectable or refractory cases...
  42. doi Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma
    Nalan Akyurek
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 41:1448-55. 2010
    ..We conclude that CKS-1B is commonly expressed in mantle cell lymphoma, particularly in aggressive histologic variants, and may be involved in pathogenesis...
  43. ncbi Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16)
    Samer Z Al-Quran
    Department of Anatomic Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Arch Pathol Lab Med 130:862-6. 2006
    ..A high index of suspicion is required to establish the diagnosis of MS involving bladder. Cytogenetic analysis is useful for both demonstrating minimal marrow disease and classifying MS in paraffin-embedded tissue sections...
  44. ncbi Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma
    C Cameron Yin
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 20:1-7. 2007
    ..These results support the concept that blastoid MCL arising in patients with typical MCL represents histologic transformation of the original neoplastic clone...
  45. ncbi MALT lymphoma involving the kidney: a report of 10 cases and review of the literature
    Mar Garcia
    The Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Pathol 128:464-73. 2007
    ..Our results indicate that kidney MALT lymphomas share similarities with MALT lymphomas arising at other sites in that MALT lymphoma-associated translocations and NF-kappaB activation occur in a subset of cases...
  46. doi Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome
    Steven A Gustafson
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 131:647-55. 2009
    ..002). These findings suggest that t-AML-t(8;21) shares many features with de novo AML-t(8;21)(q22;q22), but affected patients have a worse outcome...
  47. ncbi t(8;13)-positive bilineal lymphomas: report of 6 cases
    Francisco Vega
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 32:14-20. 2008
    ..They likely arise from an early hematopoietic cell with potential to differentiate along T-cell and myeloid pathways...
  48. ncbi Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data
    Lynne V Abruzzo
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biotechniques 38:785-92. 2005
    ..After normalizing to the geometric mean of the unvarying genes, the correlation between real-time RT-PCR and microarrays was high for genes that were moderately expressed and varied across samples...
  49. ncbi Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia
    Ankita Patel
    Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77024, USA
    Am J Hematol 83:540-6. 2008
    ..Furthermore, this pilot study clearly shows the robustness, high sensitivity, and high specificity for the targeted CLL microarray analysis as well as the potential for use in routine screening in CLL...
  50. ncbi Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma
    Joseph D Khoury
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg Pathol 28:489-95. 2004
    ..Although the best terminology for these bone marrow lymphomas is uncertain, the aggressive clinical behavior of these neoplasms supports the need for intensive therapy...
  51. ncbi Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression
    Joseph D Khoury
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    J Pathol 199:90-7. 2003
    ..002). It is concluded that expression of Mcl-1 in MCL is heterogeneous. A relatively high level of Mcl-1 expression correlates with high-grade morphology, a high proliferative state, and p53 overexpression...
  52. ncbi Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization
    Kayuri U Patel
    Department of Pathology at Texas Children s Hospital and Baylor College of Medicine, Houston, TX 77030, USA
    Hum Pathol 39:184-93. 2008
    ..Its detection may be particularly helpful in the differential diagnosis of atypical, fibrosarcomatous, and metastatic DFSP...
  53. pmc Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia
    Rachel Sargent
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    J Mol Diagn 11:25-34. 2009
    ..Further, a customized array design can provide comprehensive genomic profiling with additional accuracy in both identifying and defining the extent of small aberrations at target loci...
  54. ncbi MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast
    Sameer S Talwalkar
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 19:1402-8. 2006
    ..In contrast, breast diffuse large B-cell lymphomas are heterogeneous. Weak cytoplasmic BCL-10 staining in most cases and evidence of NF-kappaB p50 activation in a subset differs from breast MALT lymphomas...
  55. ncbi Identifying and quantifying sources of variation in microarray data using high-density cDNA membrane arrays
    Kevin R Coombes
    Department of Biostatistics, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    J Comput Biol 9:655-69. 2002
    ..The effects of exposure time, which were partly attributable to variation in the scanning process, can be minimized by using the same exposure time for all experiments...
  56. ncbi Novel translocation in acute megakaryoblastic leukemia (AML-M7)
    Jeffrey A Toretsky
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
    J Pediatr Hematol Oncol 25:396-402. 2003
    ..2-q13),+10,t(12;16)(p13;q24),-14[2], del(14)(q13)[2],+der(19)t(1;19)(?;p13.3),+22[cp 4]. AML-M7 in non-Down syndrome patients is a rare disease that requires improved prognostic markers...
  57. ncbi High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia
    Helen McCarthy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 101:4903-8. 2003
    ..Of 8 CLL cases that highly expressed AID, 7 were unmutated, suggesting that this subset may arise from GC-experienced B cells with inactive somatic hypermutation, and may predict prognosis...
  58. pmc Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia
    Shelly R Gunn
    The University of Texas Health Science Center at San Antonio, Department of Pathology, Mail Code 7750, 7703 Floyd Curl Dr, San Antonio, TX, USA
    J Mol Diagn 10:442-51. 2008
    ..5%); 13 hybridizations (4.5%) were discordant because of clonal populations that comprised less than 30% of the sample. Array CGH is a powerful, cost-effective tool for genome-wide risk assessment in the clinical evaluation of CLL...

Research Grants3

  1. Validation of RNA and DNA Biomarkers of Prognosis in Chronic Lymphocytic Leukemia
    Lynne Abruzzo; Fiscal Year: 2006
    ..We are attempting to devise a new clinical test, based on new discoveries in molecular medicine, to help doctors identify patients who may need aggressive therapy early in their disease course. ..
  2. Validation of RNA and DNA Biomarkers of Prognosis in Chronic Lymphocytic Leukemia
    Lynne Abruzzo; Fiscal Year: 2007
    ..We are attempting to devise a new clinical test, based on new discoveries in molecular medicine, to help doctors identify patients who may need aggressive therapy early in their disease course. ..